StreetInsider.com News Articles

Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald Post Tilrekimig Ph2 Data

Fri, 02 Oct 2026 07:14:03 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Aclaris Therapeutis (NASDAQ: ACRS).

The analyst commented, "At EADV, Pfizer (PFE, Neutral, covered by C. Gould) presented the Ph2 atopic dermatitis trial for tilrekimig (TSLP x IL-4 x IL-13 trispecific). ACRS was down 15% on this update (XBI: -2%). This also has implications for Aclaris since it has a TSLP x IL-4R bispecific in Ph1 for atopic derm and asthma (proof-of-concept readout in 4Q'26). We already knew the topline EASI-75 efficacy for tilrekimig, which looked very strong at ~50% placebo-adjusted at 16 weeks."

For an analyst ratings summary and ratings history on

Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald

Thu, 24 Sep 2026 07:03:23 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Aclaris Therapeutis (NASDAQ: ACRS).
The analyst commented, "KOLs sounded very confident that modzatinib (oral ITK/JAK3) should work across all LP subtypes (~100-300K addressable patients in the U.S., by our estimate). KOLs also liked Aclaris' development strategy of testing modzatinib in oral mucosal LP first, as responses can be rapid in this subtype. Just ~4-5K LP patients would make modzatinib a blockbuster drug. ~$1B in peak sales implies ~$2-3B of NPV for the LP indication alone, versus ~$800M market cap for ACRS. Not much is priced into the stock, so there

Form SCHEDULE 13G Aclaris Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.

Mon, 21 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260921/27085435.html

Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald

Wed, 16 Sep 2026 07:53:33 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Aclaris Therapeutis (NASDAQ: ACRS).

The analyst commented, "Our KOLs like that ITK targets TH2/TH17, while leaving TH1 intact, and are impressed with the Phase 1 data showing complete clearance in previously refractory patients. Dr. Cameron sees this as potentially JAK-like efficacy without a JAK-like safety profile. ACRS (OW, PA) also has selective ITK inhibitor drugs for atopic derm moving into the clinic later this year."

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Thu, 03 Sep 2026 08:00:00 -0400

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Thu, 03 Sep 2026 08:00:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris

Canaccord Starts Aclaris Therapeutis (ACRS) at Buy

Tue, 01 Sep 2026 07:02:48 -0400

(Updated - September 1, 2026 7:02 AM EDT)

Canaccord analyst Edward Nash initiates coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Buy rating and a price target of $10.00.

The analyst comments "We are initiating coverage of Aclaris Therapeutics with a BUY rating and a 12-month price target of $10. We view Aclaris as a catalyst-rich immunology & inflammatory (I&I) company approaching the point at which patient data could help determine the value of its pipeline. Our valuation of the company is concentrated on four U.S. opportunities: ATI-052 in asthma and atopic dermatitis (AD), bosakitug in AD, and modzatinib in lichen planus

Canaccord Starts Aclaris Therapeutis (ACRS) at Buy

Tue, 01 Sep 2026 07:02:48 -0400

(Updated - September 1, 2026 7:02 AM EDT)

Canaccord analyst Edward Nash initiates coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Buy rating and a price target of $10.00.

Piper Sandler on Aclaris Therapeutis (ACRS): 'Efficacy Differentiation Could Drive Share Re-Rate'

Mon, 31 Aug 2026 08:52:42 -0400

Piper Sandler analyst Biren Amin reiterated an Overweight rating and $11.00 price target on Aclaris Therapeutis (NASDAQ: ACRS).

The analyst commented: "Efficacy Differentiation Could Drive Share Re-Rate; ATI-052’s upcoming Ph1b asthma readout in 2H26 will represent an important proof point for ACRS’ dual TSLP × IL-4Rα strategy ahead of planned Ph2b asthma study initiation in 4Q26. The clearest bar to watch is a placebo-adjusted FeNO reduction of ~40 ppb at Day 29, supported by directional FEV1 improvement of ~150 mL vs pbo and favorable TARC and eosinophil trends. Results at or above these benchmarks, particularly the company’s stated FeNO and FEV1

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26931991.html

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26931991.html

Form 8-K Aclaris Therapeutics, For: Aug 06

Thu, 06 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26885550.html

Form 8-K Aclaris Therapeutics, For: Aug 06

Thu, 06 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26885550.html

Form S-3ASR Aclaris Therapeutics,

Thu, 06 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26885451.html

Form S-3ASR Aclaris Therapeutics,

Thu, 06 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26885451.html

FDA grants fast track status to Aclaris drug for lichen planus

Thu, 06 Aug 2026 16:36:20 -0400

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation for its drug candidate modzatinib (ATI-2138) for the treatment of moderate to severe lichen planus (LP), including oral erosive LP, cutaneous LP, and lichen planopilaris.

The designation covers a condition for which no therapies are currently approved. Fast Track status is intended to facilitate development and expedite review of therapies that treat serious conditions and address unmet medical needs. It allows for more frequent interactions with the FDA on development plans and clinical trial design, and permits rolling review of a New Drug

FDA grants fast track status to Aclaris drug for lichen planus

Thu, 06 Aug 2026 16:36:20 -0400

FDA grants fast track status to Aclaris drug for lichen planus

Thu, 06 Aug 2026 16:36:20 -0400

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Thu, 06 Aug 2026 16:35:00 -0400

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Aclaris expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026.

Fast Track designation is intended to facilitate the development and expedite the review of investigational therapies

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Thu, 06 Aug 2026 16:35:00 -0400

Fast Track designation is intended to facilitate the development and expedite the review of investigational therapies

Form 10-Q Aclaris Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260806/26884769.html

Form 10-Q Aclaris Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260806/26884769.html

Form 8-K Aclaris Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26878658.html

Form 8-K Aclaris Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260806/26878658.html

Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c

Thu, 06 Aug 2026 07:05:09 -0400

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.38 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.